title: Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants.
abstract: Cerebral palsy is a leading cause of childhood neuromotor disability and is strongly associated with preterm delivery. Basic science research and some observational studies have suggested a neuroprotective benefit from antenatal exposure to magnesium sulfate. Recent randomized controlled studies and meta-analyses suggest that antenatal exposure to magnesium sulfate before anticipated preterm birth is associated with reduction in the risk of developing cerebral palsy or its associated neurologic disabilities in surviving infants. More importantly. this benefit has been achieved without increasing the risk of perinatal mortality.
authors.affiliation: Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0587, USA. mmcostan@utmb.edu
authors.forename: Maged M
authors.initials: MM
authors.lastname: Costantine
authors.forename: Nathan
authors.initials: N
authors.lastname: Drever
mesh_terms: D002547:Cerebral Palsy / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011247:Pregnancy; D011295:Prenatal Care; D015149:Tocolytic Agents / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D015149:Tocolytic Agents; D008278:Magnesium Sulfate